Patient-Derived Multiple Myeloma 3D Models for Personalized Medicine—Are We There Yet?
Open Access
- 25 October 2022
- journal article
- review article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 23 (21) , 12888
Abstract
Despite the wide variety of existing therapies, multiple myeloma (MM) remains a disease with dismal prognosis. Choosing the right treatment for each patient remains one of the major challenges. A new approach being explored is the use of ex vivo models for personalized medicine. Two-dimensional culture or animal models often fail to predict clinical outcomes. Three-dimensional ex vivo models using patients’ bone marrow (BM) cells may better reproduce the complexity and heterogeneity of the BM microenvironment. Here, we review the strengths and limitations of currently existing patient-derived ex vivo three-dimensional MM models. We analyze their biochemical and biophysical properties, molecular and cellular characteristics, as well as their potential for drug testing and identification of disease biomarkers. Furthermore, we discuss the remaining challenges and give some insight on how to achieve a more biomimetic and accurate MM BM model. Overall, there is still a need for standardized culture methods and refined readout techniques. Including both myeloma and other cells of the BM microenvironment in a simple and reproducible three-dimensional scaffold is the key to faithfully mapping and examining the relationship between these players in MM. This will allow a patient-personalized profile, providing a powerful tool for clinical and research applications.Keywords
Funding Information
- Fundação para a Ciência e a Tecnologia (PTDC/MED-ONC/1215/2021/PT)
This publication has 198 references indexed in Scilit:
- Pomalidomide: the new immunomodulatory agent for the treatment of multiple myelomaBlood Cancer Journal, 2013
- Randomized Phase II Trials: A Long-term Investment With Promising ReturnsJNCI: Journal of the National Cancer Institute, 2011
- Guidelines for the welfare and use of animals in cancer researchBritish Journal of Cancer, 2010
- Collagen-based cell migration models in vitro and in vivoSeminars in Cell & Developmental Biology, 2009
- CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapyBlood, 2009
- The anti-cancer drug lenalidomide inhibits angiogenesis and metastasis via multiple inhibitory effects on endothelial cell function in normoxic and hypoxic conditionsMicrovascular Research, 2009
- Improved survival in multiple myeloma and the impact of novel therapiesBlood, 2008
- Clonogenic Multiple Myeloma Progenitors, Stem Cell Properties, and Drug ResistanceCancer Research, 2008
- Checkpoint Blockade in Cancer Immunotherapy2006
- Primary Bioassay of Human Tumor Stem CellsScience, 1977